Stock Track | AKESO Plummets 5.08% Intraday on Disappointing Ivonescimab Phase III Trial Results

Stock Track

May 22

AKESO's stock plummeted 5.08% during intraday trading on Friday, reflecting continued market concerns over clinical trial setbacks for its key drug candidate.

The decline follows disappointing interim results from the HARMONi-3 global pivotal Phase III study of AKESO's core product ivonescimab. The interim analysis targeting squamous cell carcinoma in first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold for progression-free survival, raising persistent concerns about whether the superior clinical results observed in the Chinese population can be replicated globally.

Market sentiment has been negatively impacted by this development, with AKESO's overseas partner Summit previously experiencing a stock plunge of over 25% following the same disclosure. The stock's performance contrasts with the broader biotech sector, which showed mixed-to-positive movement on the same trading day.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1173621327"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173621327\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173621327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173621327","market":"hk","top_or_hot":-1,"title":"Stock Track | AKESO Plummets 5.08% Intraday on Disappointing Ivonescimab Phase III Trial Results","media":"Stock Track","content":"<p>AKESO's stock plummeted 5.08% during intraday trading on Friday, reflecting continued market concerns over clinical trial setbacks for its key drug candidate.</p><p>The decline follows disappointing interim results from the HARMONi-3 global pivotal Phase III study of AKESO's core product ivonescimab. The interim analysis targeting squamous cell carcinoma in first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold for progression-free survival, raising persistent concerns about whether the superior clinical results observed in the Chinese population can be replicated globally.</p><p>Market sentiment has been negatively impacted by this development, with AKESO's overseas partner Summit previously experiencing a stock plunge of over 25% following the same disclosure. The stock's performance contrasts with the broader biotech sector, which showed mixed-to-positive movement on the same trading day.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Plummets 5.08% Intraday on Disappointing Ivonescimab Phase III Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Plummets 5.08% Intraday on Disappointing Ivonescimab Phase III Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-22 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock plummeted 5.08% during intraday trading on Friday, reflecting continued market concerns over clinical trial setbacks for its key drug candidate.</p><p>The decline follows disappointing interim results from the HARMONi-3 global pivotal Phase III study of AKESO's core product ivonescimab. The interim analysis targeting squamous cell carcinoma in first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold for progression-free survival, raising persistent concerns about whether the superior clinical results observed in the Chinese population can be replicated globally.</p><p>Market sentiment has been negatively impacted by this development, with AKESO's overseas partner Summit previously experiencing a stock plunge of over 25% following the same disclosure. The stock's performance contrasts with the broader biotech sector, which showed mixed-to-positive movement on the same trading day.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1173621327","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173621327","pubTimestamp":1779415121,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock plummeted 5.08% during intraday trading on Friday, reflecting continued market concerns over clinical trial setbacks for its key drug candidate.The decline follows disappointing interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"股票追踪|ivonescimab III期试验结果令人失望康方生物盘中暴跌5.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock plummeted 5.08% during intraday trading on Friday, reflecting continued market concerns over clinical trial setbacks for its key drug candidate.The decline follows disappointing interim results from the HARMONi-3 global pivotal Phase III study of AKESO's core product ivonescimab. The interim analysis targeting squamous cell carcinoma in first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold for progression-free survival, raising persistent concerns about whether the superior clinical results observed in the Chinese population can be replicated globally.Market sentiment has been negatively impacted by this development, with AKESO's overseas partner Summit previously experiencing a stock plunge of over 25% following the same disclosure. The stock's performance contrasts with the broader biotech sector, which showed mixed-to-positive movement on the same trading day.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}